Accessibility Tools
Invert colors
Monochrome
Dark contrast
Light contrast
Low saturation
High saturation
Highlight links
Highlight headings
Screen reader
Read mode
Content scaling
100
%
Font size
100
%
Line height
100
%
Letter spacing
100
%
(678) 384-7220
info@geovax.com
About Us
Company
Management
Board of Directors
Scientific Advisory Board
Technology
MVA-VLP Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Immuno-Oncology
Infectious Diseases
Collaborators
Investors
Corporate Profile
News
Events
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
News & Media
Contact
Contact Us
Careers
SEC Filings
SEC Filings
Year
2022
Date
06-13
Description
Other Definitive Proxy Statement
SEC Form
DEF 14A
Download Word
Download Excel
Download PDF
GeoVax_DEF_14A__2022_Annual_Meeting_.pdf
id
About GeoVax
Company
Management
Board of Directors
Scientific Advisory Board
Our Technology
Technology Overview
Publications
Investors
Corporate Profile
News
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
Product Pipeline
Pipeline Summary
Immuno-Oncology
Infectious Diseases
Collaborators
SUBSCRIBE FOR UPDATES FROM GEOVAX
Register to receive email alerts for GeoVax press releases
SUBMIT
Email
Search
About Us
Company
Management
Board of Directors
Scientific Advisory Board
Technology
MVA-VLP Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Immuno-Oncology
Infectious Diseases
Collaborators
Investors
Corporate Profile
News
Events
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
News & Media
Contact
Contact Us
Careers
